People who search for a pain management clinic have often been in pain for months or years. Many have tried several treatments already, some are worried about medications, and some have been turned away elsewhere. They want a clinic that will take them seriously and explain their options honestly.
Pain management is also one of the most closely watched areas in health care advertising. Medications, procedures and newer treatments each carry their own rules. This guide covers how to describe your approach without making clinical claims, what Google allows, FTC rules on claims and patient stories, referral and free offer rules, and HIPAA. It does not cover prescribing, dosing or which treatment suits which patient, which are clinical decisions for licensed clinicians. Clinics that offer PEMF should also read our guide to PEMF therapy marketing rules. For pain pages written without stigma, see sickle cell center marketing.
This is general information, not legal or medical advice. Sources cited were checked on October 28 and 29, 2026: the CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (MMWR, November 4, 2022, read from an Internet Archive copy of October 23, 2026, because cdc.gov blocked our automated check), the Google Ads Healthcare and medicines policy, the FTC Health Products Compliance Guidance, 16 CFR 255.2 and Part 465, 42 U.S.C. 1320a-7a and 1320a-7b(b), and 45 CFR 164.508. Prescribing, telehealth and controlled substance rules are set by federal and state law and change. Have a health care attorney review your marketing. If you or someone you know is in crisis, call or text 988.
Describe your approach, not outcomes
The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain is written for clinicians, not for marketing, but it shapes what patients read and what payers expect. CDC says its recommendations are voluntary and are intended to support, not supplant, individualized, person-centered care, and that they should not be used as inflexible standards of care. It also says nonopioid therapies are preferred for subacute and chronic pain, and that clinicians should maximize the use of nonpharmacologic and nonopioid pharmacologic therapies as appropriate for the specific condition and patient.
That gives a clinic honest, defensible language: care is individualized, plans are built with the patient, and many options are considered. It does not support marketing that promises an end to pain, positions any single treatment as the answer for everyone, or suggests a clinic will or will not prescribe particular medications before a patient is evaluated.
- Avoid pain-free, cure, permanent relief and similar promises.
- Do not advertise medications, and never imply that a visit leads to a prescription.
- Describe the process: evaluation, a plan built with the patient, the types of services you offer, follow-up and coordination with the patient’s other clinicians.
- Name the clinicians and their credentials accurately.
What Google allows
Google’s Healthcare and medicines policy says Google does not allow ads promoting or selling prescription opioid painkillers, with a separate rule for medication-assisted treatment of opioid use disorder. Prescription drug terms in general are restricted in ads, landing pages and keywords.
The same policy does not allow promotion of speculative or experimental medical treatments, or of cell or gene therapies, except that in the United States Google allows promotion of FDA licensed or approved cell or gene therapies by entities that hold that license or approval, and allows purely educational or informational ads about them. Pain practices that offer newer injection-based or regenerative services should check carefully how those services are described before any campaign.
Ads about the practice itself, such as a consultation with a pain specialist, the conditions you evaluate and how to book, usually avoid these problems. Our Google Ads for practices page explains how we plan campaigns around restricted categories, and our guide to healthcare ad policy basics covers the main platforms.
Claims and patient stories
The FTC Health Products Compliance Guidance says claims about the health benefits of health-related products and services require competent and reliable scientific evidence, and that advertisers are responsible for implied claims as well as express ones. A headline about a patient who walked again, or a list of conditions next to the word relief, can imply results.
Under 16 CFR 255.2(b), an ad that relates one patient’s experience on a key point is likely to be read as typical. Without substantiation, the ad should clearly disclose the generally expected results. Patient stories also need a written authorization under 45 CFR 164.508 if your practice is a HIPAA covered entity. Our guide to patient testimonials covers both rules.
16 CFR Part 465 prohibits fake reviews and, in section 465.4, incentives conditioned on reviews expressing a particular sentiment. In replies, never confirm that a reviewer is a patient or mention their treatment; see our guide to replying to patient reviews.
Spine surgery has its own advertising questions, from “laser” labels and outpatient recovery claims to procedure prices. See our laser spine surgery advertising guide.
Referrals and free offers
Pain practices often see many Medicare patients and depend on referrals. The federal anti-kickback statute, 42 U.S.C. 1320a-7b(b), makes it a crime to knowingly and willfully offer or pay remuneration to induce referrals of items or services payable by a federal health care program. Do not give referral sources anything of value tied to referrals; our guide to patient and physician referrals explains the basics.
For patients, 42 U.S.C. 1320a-7a(a)(5) penalizes offering Medicare or Medicaid beneficiaries remuneration likely to influence their choice of provider, and defines remuneration to include items and services given free or for less than fair market value. Free consultations, free screenings or transportation offers aimed at Medicare patients should be reviewed by counsel before you advertise them.
Telehealth and controlled substances
If your practice offers telehealth, the federal rules on prescribing controlled substances by telemedicine have been extended in stages and are scheduled to change. Our guide to telehealth marketing for practices tracks the current dates. Do not market telehealth as a way to obtain any particular medication.
What tends to work, inside the rules
- Condition and service pages. What a condition is in plain terms, how your clinicians evaluate it, and the kinds of services you offer, with no outcome promises.
- A clear first visit page. What to bring, including records and imaging, how long the visit takes, and what happens next.
- Clinician pages. Training, board certifications as actually held, and the care each clinician focuses on.
- Referral relationships done right. Information for primary care and specialists about what you do and how to refer, with nothing of value tied to referrals.
- Fast, careful answers. Staff or an AI front desk can handle scheduling and insurance questions and hand anything about symptoms or medications to the clinical team.
Can a pain clinic advertise that it prescribes opioids?
No. Google does not allow ads promoting or selling prescription opioid painkillers, and promising a prescription before an evaluation is not appropriate in any channel.
Can we advertise stem cell or regenerative treatments for pain?
Google does not allow promotion of speculative or experimental treatments or of cell and gene therapies, except FDA licensed or approved products promoted by the license holder, and purely educational content. Check each service with counsel before advertising.
Can we say our clinic follows the CDC guideline?
You can say clinicians use current guidelines to inform individualized care. CDC itself says its 2022 recommendations are voluntary and should not be used as inflexible standards, so avoid presenting them as a promise about any patient’s treatment.
Can we offer a free consultation?
Be careful with Medicare and Medicaid patients. 42 U.S.C. 1320a-7a(a)(5) covers free items and services likely to influence a beneficiary’s choice of provider. Have counsel review the offer.
Can we share a patient’s recovery story?
Only with written authorization under 45 CFR 164.508 where HIPAA applies, and under 16 CFR 255.2(b) disclose generally expected results unless the story is substantiated as typical.
Sources
- CDC: Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (MMWR, November 4, 2022)
- Internet Archive copy of the CDC guideline, October 23, 2026
- Google Ads: Healthcare and medicines policy
- FTC: Health Products Compliance Guidance (December 2022)
- 16 CFR 255.2: Consumer endorsements
- 16 CFR Part 465: Use of consumer reviews and testimonials
- 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs (anti-kickback statute, subsection b)
- 42 U.S.C. 1320a-7a: Civil monetary penalties (beneficiary inducement, subsection a(5))
- 45 CFR 164.508: Uses and disclosures for which an authorization is required
- SAMHSA: 988 Suicide and Crisis Lifeline
More in Physician specialty marketing